Category Archives: Pharmacogenomics

Clover Health similar to many other Medicare Advantage (MA) players has its sights firmly set on the home.

But unlike its larger and older MA peers, the relatively smaller and newer Clover isnt held back by certain structural constraints. That ability to build a home-focused model from the ground up is a big part of Clovers future, Chief Scientific Officer Kumar Dharmarajan told Home Health Care News.

And the technology-enabled Clovers future is bright: Founded in 2013, San Francisco-based Clover has raised about $925 million since launching. Among its backers: Google parent company Alphabet Inc. (Nasdaq: GOOGL).

HHCN recently caught up with Clovers Dharmarajan to learn all about its in-home care ambitions, its approach to partnerships and evolution into a payer-provider hybrid.

Highlights from that conversation are below, edited for length and clarity.

Dharmarajan: If youre asking about specific bids and plan offerings, those vary by location. Clover doesnt just have one U.S. plan, in other words.

We have a number of different offerings where we engage with members in the home. One of those is our in-home care program, where we provide in-home primary care services for some of our most vulnerable members, people with multiple chronic conditions, frailty and advanced illness.

Many of these folks are frequently hospitalized and have limited life expectancies. For those members, we wanted to provide a technology-enabled house calls experience. House calls have been shown by CMS and some of its demos to be really important to those who have trouble accessing care, including those who are homebound.

Advertisement

Many of the Clover members in this program do have difficulty leaving the home.

We give them access to physicians, nurses, social workers people who will see them monthly if needed. Theyll spend an hour or so at a time with our members. Contrast that to getting 10 minutes with your doctor in the office.

We focus on very comprehensive, holistic care thats aligned with members values, preferences and prognosis. We provide a number of interventions that are on the cutting-edge side.

We do pharmacogenomics testings. We want to make sure members medication regimens are best-aligned with how their bodies metabolize drugs. A lot of folks are on 10, 15 medications.

In some of these cases, its like a witchs brew, right? We want to make sure the regimen our members are on promotes their health and doesnt cause side effects.

For some of our members, we also give them access to what we call the Clover button, which is an ability for them to contact their provider directly. They dont have to remember a phone number. They just press a button, then they could talk through that and speak with their medical team.

And we do a bunch of other things where we really integrate payer and provider. Clover is a technology-enabled health insurance company, but this in-home care practice, this house calls practice is wholly owned by Clover.

Clover the health plan has access to a lot of different streams of medical information that we provide to Clover the practice.

For example, we often know when a member of ours is hospitalized or heads to the ER. We can get real-time data feeds a lot of times from those institutions. We then feed that info to the medical practice so they know exactly when a person leaves. In turn, we can engage with those individuals in the home as soon as theyre discharged.

Were really excited about that partnership between plan and provider.

At this point, Clover does not provide skilled home health services and things that fall into that bucket. We do have social workers who see our members and help with financial challenges. We have nurses who are part of our team, experts who are well-trained in, for example, wound management.

Were not trying to be a home health agency, but we do have some of those skillsets naturally within the team. And we do partner with home health agencies to really advance the care of our members.

In general, home health is probably underutilized for a lot of frail elders. We look to use home health care wherever it could benefit a member.

Unfortunately, its not a coincidence that some of the sickest, most vulnerable patients are also the most vulnerable from a social perspective, whether thats in regard to finances, housing, food or language barriers. For us, addressing social determinants is just part and parcel of the practice.

Its not something that we see as a unique strategy or something new that we need to suddenly start doing.

Its certainly en vogue now to talk about addressing social determinants of health. We just think its always been very core to the model of, you know, improving care for homebound older adults.

Regardless of that, committing to a home-based strategy is something that Clover has been interested in doing and has been investing in for some time. Home-based care is very scalable compared to brick and mortar.

Its also clear to us that home-based care allows you to pick up on and address issues that you would never see in an office setting. You go into the home of an older adult, you see six different bottles of insulin, all of which are different. This literally just happened with one of our members, who was actually blind. She didnt know which [insulin] to take.

When you go into the home, you see that. You can see whats in the refrigerator. You can engage with family members. Theres an incredible amount of data.

With our in-home care program, weve seen reductions in [hospital] admission rates, reductions in ER visitation rates. Weve seen reduced medical expenses overall. And weve heard from a lot of members who are just positive and grateful for the program.

Many people have never had house calls before.

I dont think I can tell you our specific partners at this point. But generally, I think there are a few things that are very important to us.

One is responsiveness. If you have a home health need, being able to quickly make the referral and have a team get in there ASAP is so critical.

Also having bi-directional communication is important. Once the home health provider is in there working with our member, we want to hear from that provider if they see something theyre concerned with. Even if its just, The member doesnt look at good today.

Provider groups need to be collaborators and, in a sense, sensors. Home health providers might be in the home more frequently than we are, depending on a members needs.

We have spoken with some and have embarked on some pilots. We do recognize that non-skilled services are an important part of the overall picture.

Read more:
Alphabet-Backed Insurer Clover Health Committing to Home-Based Strategy - Home Health Care News

Progress in genomic science has been astronomical over the past few years. In fact, the tipping point that validated the clinical significance of genetic/genomic testing is barely visible in the rearview mirror. As a result, stakeholders ranging from clinicians to regulatory agencies, to professional associations, to payers have begun championing the value that precision medicine delivers in terms of better diagnoses and more effective therapeutic interventions.

For example, in educational materials explaining incidence of dilated cardiomyopathy (DCM), the American Heart Association notes that a full third of DCM patients inherit the condition from their parents or other family members. Germline testing can identify patients with this genetic variant, leading clinicians to a faster diagnosis and earlier treatment. The Food and Drug Administration (FDA) has stated its commitment to approving targeted therapies based on genetic mutations as appropriate. Payers are beginning to issue reimbursement policies to cover the cost of genetic/genomic testing. United Healthcare, for instance, began covering pharmacogenomic panels for patients with anxiety and depression this October.

This leads us to the next great transformation necessitated by precision medicine: implementing the technology infrastructure to govern the ordering and resulting processes inherent to genomics, as well as finding ways to manage the great volumes of data generated by testing.

Precision medicine is already being pursued sporadically across many, if not most, healthcare organizations. Oncologists are likely to be ordering somatic tests to better profile patient tumors so targeted therapies can be delivered. Family practice, behavioral medicine and psychiatric departments are using pharmacogenomics to understand how well (or poorly) patients metabolize specific medications and which might trigger side effects or safety concerns. These insights allow them to prescribe the right treatment at the right dose the first time around instead of spending months on a trial-and-error approach.

Cardiovascular and neurology specialists (among others) order germline tests to help them diagnose, treat and gain new insights into many common conditions such as congestive heart failure, arrhythmias, aneurysms, epilepsy, nerve pain and dementia. Some health systems even order germline tests on all newborns so a full genetic profile is available which can be used throughout the individuals lifetime.

The value of the data being generated through these clinical pockets cannot be understated. It carries information that can be used across a multitude of care settings far into the future to help providers and specialists arrive at more accurate diagnoses faster, and identify the most effective treatment sooner. This, in turn, can help healthcare leaders move the needle to improve quality efforts and optimize revenue while reducing the risk associated with poor outcomes.

To realize full value, however, healthcare organizations must ensure genetic/genomic test results are readily available to clinicians at the point of care and in a vocabulary that makes them meaningful. Unfortunately, few health systems have invested in the IT resources that can make this possible. Currently, test results are ordered in a vacuum and results are often returned in a PDF that will be hard to access. In addition, the information is relayed in a nomenclature unfamiliar to clinicians, so they struggle to understand how to apply the results to specific patient circumstances.

Unless these concerns are addressed, healthcare will simply reenact a mistake made years ago with the advent of electronic health records: valuable data that can immediately and directly impact care will be locked in a silo, unavailable during clinical decision-making.

As the industry heads into 2020, it must make plans and take action to get ahead of this looming problem. Healthcare IT professionals must be brought to the table to help organizations strategize about their precision medicine initiatives. The key to success with this new standard of care is recognition that data generated by genetic/genomic tests can be used endlessly across the enterprise and over the long term as patient conditions change. Organizations must seek out platforms that will consume genomic test results as discrete data and integrate it with patient-specific clinical information. Likewise, the platforms must be made available within existing workflows, so clinicians can leverage it during decision making and can interrogate the data as patient conditions change and genomic science delivers new insights.

Picture: Feodora Chiosea, Getty Images

Read the original:
IT will be key to precision medicine's success in 2020 - MedCity News

The market research reportPharmacogenomics Marketevaluates the historical, the latest values and current changes to predict the market for the coming years from 2019 to 2026.

Our specific research examiners have been prepared to direct their exploration needs to the right research assets and to add a unique advantage over their rivals. We give scholarly, precise and important information in the lightning.

The main actors focus their efforts on developing ongoing innovations aimed at improving skills and realistic turnaround times. The best long-term development opportunities for this area can be captured by ensuring continuous process upgrades and adaptability with financial resources to put resources in the right methodologies.

Get HOLISTIC Request Sample Copy:https://www.coherentmarketinsights.com/insight/request-sample/1053

The report allows you to:

Recognize and learn from important and distinct types of underdevelopment

Formulate competitor reports, market analyzes and significant information to improve R & D strategies

Develop tactics for market entry and market expansion

Plan Mergers and Acquisitions Effectively by Identifying Key Players in the Most Promising Pipeline

This market report should develop within the estimated time frame, with the compound annual growth rate increasing considerably. The aim of the market research report is to determine the current state of the global market for Pharmacogenomics and, according to this ranking, classify it into a few parts. The report takes into account the main players in the industry in all areas of the world.

Reasons to invest in this report:

Develop / modify small business development strategies using substantial growth offering emerging and developed markets.

Highlights key industry priorities to help organizations realign their business strategies.

Save less time to undertake an entry-level study by identifying the extension, dimensions, major players, and sections.

Encourage the decision-making process in the global market by including projects that demonstrate commercial interest in services and products, segmentation and vertical markets.

Has studied global trends and forecasts of the global market, as well as all the factors that direct the current activity, in addition to those that endanger it.

Download PDFBrochure withIn-Depth Study of TOC: https://www.coherentmarketinsights.com/insight/request-pdf/1053

About us:

Coherent Market Insights is a leading market research and advisory firm offering ready-made underwriting research reports, customized market research, consulting and competitive analysis through a variety of industry trend recommendations. emerging markets, technologies and potential opportunities in absolute dollars.

Link:
Pharmacogenomics Market be Impacted by Rising Adoption of Automated Diagnostic Devices in Healthcare Industry - Industry Updates Daily

PARSIPPANY, NJ, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss the Companys financial results and provide a general business update.

All listeners should confirm they are dialing in for the Interpace conference call with the operator who will promptly place them into the call. A webcast replay will be available on the companys website (www.interpacediagnostics.com) approximately two hours following completion of the call and will be archived on the companys website for 90 days.

About Interpace, Inc.

Interpace is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpaces Diagnostic Business is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDXthat differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Interpaces Biopharma Business is a market leader in providing pharmacogenomics testing, genotyping, and biorepository services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpaces website at http://www.interpacediagnostics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Story continues

CONTACTS:Investor Relations - Edison GroupJoseph Green(646) 653-7030jgreen@edisongroup.com

Visit link:
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019 - Yahoo Finance

Global Genealogy Products and Services Market A Report by Fact.MR

Fact.MR, in its latest business intelligence study, depicts the nuts and bolts of the global genealogy products and services market. The genealogy products and services market report presents detailed information regarding the drivers, restraints, opportunities and trends affecting market growth. Each segment along with its sub-segment is analyzed in terms of value and volume. Further, the genealogy products and services market report elaborates the market behavior of each vendor operating in the genealogy products and services market.

The genealogy products and services market report considers the following years to present the overall market growth:

Key findings of the genealogy products and services market study:

Request Sample Report https://www.factmr.com/connectus/sample?flag=S&rep_id=3083

On the basis of category, the genealogy products and services market study consists of:

On the basis of region, the genealogy products and services market study contains:

Key players analyzed in the genealogy products and services market study:

Queries addressed in the genealogy products and services market report:

Request Methodology of this Report https://www.factmr.com/connectus/sample?flag=RM&rep_id=3083

Why choose Fact.MR?

Reports published by Fact.MR are a result of the combination of our experts and digital technologies. We thrive to provide innovative business solutions to the clients as well as tailor the reports aligning with the clients requisites. Our analysts perform comprehensive research to offer ins and outs of the current market situation. Clients across various time zones tend to utilize our 24/7 service availability.

See the original post:
Genealogy Products and Services Market Demand for Genetic Testing to Surge as Preventive Healthcare and Pharmacogenomics Gain Traction - Young...

DUBLIN--(BUSINESS WIRE)--The "The Global Genetic Testing Market by Hereditary, Newborn, NIPT, Oncology, Pharmacogenomic and Direct to Consumer, With Executive and Consultant Guides 2020 to 2024" report has been added to ResearchAndMarkets.com's offering.

This report forecasts the market size out to 2024. The report includes detailed breakouts for 14 countries and 5 regions.

Will all newborns receive Whole Genomic Sequencing at birth? What key interest is driving Direct to Consumer?

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating a new life for the industry.

Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find opportunities and pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request

Key Topics Covered

1. Introduction and Market Definition

1.1 Genetic Testing Definition in This Report

1.2 The Genomics Revolution

1.3 Market Definition

1.3.1 Revenue Market Size

1.4 U.S. Medical Market and laboratory Testing - Perspective

1.4.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

2.1 Market Participants Play Different Roles

2.1.1 Supplier/pharmaceutical

2.1.2 Independent lab specialized/esoteric

2.1.3 Independent lab national/regional

2.1.4 Independent lab analytical

2.1.5 Public National/regional lab

2.1.6 Hospital lab

2.1.7 Physician lab

2.1.8 DTC Lab

2.1.9 Independent Genetic Testing Lab

2.1.10 Audit Body

2.2 Genetic Tests -Types, Examples and Discussion

2.2.1 Preimplantation Genetic Diagnosis- An Emerging Market

2.2.2 Prenatal Diagnosis - New Technologies Create Opportunity

2.2.3 Newborn Screening

2.2.2 Diagnostic Testing

2.2.3 Carrier Testing

2.2.6 Predictive and Presymptomatic Testing

2.2.7 Pharmacogenomics

2.2.8 Forensic Testing

2.2.9 Parental Testing

2.2.10 Ancestral Testing

2.3 Industry Structure

2.3.1 Hospital's Testing Share

2.3.2 Economies of Scale

2.3.2.1 Hospital vs. Central Lab

2.3.3 Physician Office Lab's

2.3.4 Physician's and POCT

2.4 Market Shares of Key Genetics Players - Analysis

3. Market Trends

3.1 Factors Driving Growth

3.1.1 Genetic Discoveries Creating New Diagnostic Markets

3.1.2 Aging Population a Boon for Diagnostics

3.1.3 Pharmacogenomics Drives Further Growth

3.1.4 Oncology and Liquid Biopsy Enter New Era

3.1.5 Fertility Practice Growth drives market

3.1.6 Direct to Consumer begins to break out

3.2 Factors Limiting Growth

3.2.1 Increased Competition Lowers Price

3.2.2 Lower Costs

3.2.3 Testing usage analysis curtailing growth

3.2.4 Wellness has a downside

3.3 Instrumentation and Automation

3.3.1 Instruments Key to Market Share

3.3.2 Bioinformatics Plays a Role

3.4 Diagnostic Technology Development

3.4.1 Next Generation Sequencing Fuels a Revolution

3.4.2 Impact of NGS on pricing

3.4.3 POCT/Self Testing Disruptive Force

3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment

3.4.5 CGES Testing, A Brave New World

3.4.6 Biochips/Giant magnetoresistance based assay

4. Genetic Testing Recent Developments

4.1.1 Importance of This Section

4.1.2 How to Use This Section

5. Profiles of Key Companies

6. Global Market Size

6.1 Global Market by Country

6.2 Global Market by Application

7. Market Sizes by Application

7.1 Hereditary Testing Market

7.2 Newborn Testing Market

7.3 NIPT Testing Market

7.4 Oncology Testing Market

7.5 Pharmacogenomic Testing Market

7.6 Direct to Consumer Testing Market

8. The Future of Genetic Testing

For more information about this report visit https://www.researchandmarkets.com/r/2llelf

See more here:
Global Genetic Testing Markets 2020-2024 | by Hereditary, Newborn, NIPT, Oncology, Pharmacogenomic & Direct to Consumer - ResearchAndMarkets.com -...